Results 51 to 60 of about 53,817 (192)

Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. [PDF]

PLoS ONE, 2015
Expression of the tumor suppressor gene TUSC2 is reduced or absent in most lung cancers and is associated with worse overall survival. In this study, we restored TUSC2 gene expression in several wild type EGFR non-small cell lung cancer (NSCLC) cell ...
Bingbing Dai, Shaoyu Yan, Humberto Lara-Guerra, Hiroyuki Kawashima, Ryo Sakai, Gitanjali Jayachandran, Mourad Majidi, Reza Mehran, Jing Wang, B Nebiyou Bekele, Veerabhadran Baladandayuthapani, Suk-Young Yoo, Ying Wang, Jun Ying, Feng Meng, Lin Ji, Jack A Roth   +16 more
doaj   +1 more source

Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status

Frontiers in Oncology, 2022
Translational RelevanceEvaluation of targeted therapies is urgently needed for the majority of patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) who progress after immunochemotherapy.
Mercedes Porosnicu, Mercedes Porosnicu, Anderson O’Brien Cox, Joshua D. Waltonen, Paul M. Bunch, Ralph D’Agostino, Ralph D’Agostino, Thomas W. Lycan, Thomas W. Lycan, Richard Taylor, Dan W. Williams, Xiaofei Chen, Kirtikar Shukla, Brian E. Kouri, Tiffany Walker, Tiffany Walker, Gregory Kucera, Gregory Kucera, Hafiz S. Patwa, Hafiz S. Patwa, Christopher A. Sullivan, Christopher A. Sullivan, J. Dale Browne, J. Dale Browne, Cristina M. Furdui, Cristina M. Furdui   +25 more
doaj   +1 more source

Mitochondrial Morphology Dynamics Remodel Metabolism and Affect TKI Sensitivity in EGFR‐Mutated Lung Cancer

Cancer Science, EarlyView.
TKI treatment promotes mitochondrial fission and metabolic reprogramming toward oxidative phosphorylation in residual EGFR‐mutant lung cancer cells. Targeting this metabolic vulnerability restores TKI sensitivity and provides a promising strategy to overcome acquired resistance.
Yu Zhao, Yuqiang Liu, Mingxuan Xie, Zhiming Ye, Hong Huang, Maojin Yao, Feng Zhou, Jianzhu Zhao, Jun Tang   +8 more
wiley   +1 more source

Severe cicatricial alopecia as a rare cutaneous side effect due to erlotinib – case report

, 2016
Introduction . Epidermal growth factor receptor inhibitors (EGFRI) are commonly used in the treatment of solid tumors. Cutaneous side effects occur in 80% of patients and are the most frequent adverse events.
Aleksandra Batycka-Baran, Magdalena Żychowska, Wojciech Baran, Joanna Maj   +3 more
core   +1 more source

Severe megaloblastic anemia in a patient with advanced lung adenocarcinoma during treatment with erlotinib: a case report and literature review

BMC Pulmonary Medicine
Background Erlotinib is a first-generation, tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) used for the treatment patients with NSCLC.
Xin Yan, Jingxian Kong, Jiacheng Wang, Caixia Wang, Hongchang Shen   +4 more
doaj   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

Eruptive Acral Melanocytic Lesions Associated With Capecitabine

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Eruptive nevi and lentigines have been reported to occur in the setting of immunosuppression, which may be medication‐induced. The associated histopathologic findings have not been well described in the literature. Herein, we report the case of a woman in her 60s who had been receiving chemotherapy treatment with capecitabine, a prodrug of 5 ...
Madison Smith, Annie Jin, Jonathan A. Miles, Rosalie Elenitsas, Danielle M. DeHoratius, Emily Y. Chu   +5 more
wiley   +1 more source

Erlotinib inhibits glioma cell proliferation.

, 2013
(A) Representative phase-contrast micrographs of glioma cell lines left untreated (control) or treated for 48 h with 10 µM erlotinib (erlotinib). (B) Glioma cell lines were left untreated (untreated) or treated with 10 µM erlotinib (erlotinib) and the ...
Elena Thomàs-Moyà (320319), Silvia Fernández de Mattos (320320), José Rodríguez (3463523), Priam Villalonga (320321), Guillem Ramis (320318)   +4 more
core   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma [PDF]

, 2015
A liquid chromatography tandem mass spectrometry method was developed and validated for quantification of erlotinib and its metabolites in human plasma. The method is suitable for therapeutic drug monitoring and pharmacokinetic studies.
Vikingsson, Svante,, Green, Henrik, Green, Henrik,, Vikingsson, Svante, Lundeberg, Joakim,, Svedberg, Anna, Vikström, Anders,, Vikström, Anders, Lundeberg, Joakim, Svedberg, Anna,   +9 more
core   +1 more source